Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eyes With Glaucoma Clear all
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Not listed No phase listed Observational

Assessment of Visual Function With a Portable Brain-computer Interface

NCT03760055
View directory record Official record
Conditions
Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
Interventions
nGoggle
Device
Lead sponsor
NGoggle
Industry
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 21, 2026, 3:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

OCT Agreement and Precision Study

NCT02045823
View directory record Official record
Conditions
Normal Eyes, Eyes With Glaucoma, Eyes With Retinal Disease
Interventions
Not listed
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 2 Interventional

24-hour Efficacy of AR-12286

NCT01330979
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-12286 0.5% Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops

NCT01925391
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure, Anesthesia
Interventions
Tono-pen XL Applanation tonometer + Ocu-film +
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 18 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 21, 2026, 3:27 PM EDT
Recruiting Not applicable Interventional

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

NCT07147647
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
Direct Selective Laser Trabeculoplasty
Device
Lead sponsor
Select Eye Care
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Elkridge, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 21, 2026, 3:27 PM EDT
Completed No phase listed Observational

Comparing the Effect of the Water Drinking Test on Intraocular Pressure

NCT02001155
View directory record Official record
Conditions
Glaucoma
Interventions
Water Drinking Test
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT00804648
View directory record Official record
Conditions
Glaucoma, Open Angle, Ocular Hypertension
Interventions
Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Bourbonnais, Illinois • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 3:27 PM EDT
Not listed Phase 2 Interventional

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

NCT02152774
View directory record Official record
Conditions
Chronic Angle-closure Glaucoma
Interventions
Rho-Kinase Inhibitor
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

NCT00224289
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost 0.005%
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

NCT02700984
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 2 Interventional

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 21, 2026, 3:27 PM EDT
Enrolling by invitation No phase listed Observational

A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma

NCT07520175
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
AlloSpan Canal Platform Bio-Reinforced Canaloplasty
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Chico, California • Petaluma, California • Alexandria, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions

NCT01915680
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure
Interventions
Not listed
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Oct 21, 2026, 3:27 PM EDT
Completed Phase 3 Interventional

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

NCT03850782
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost (SR)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
38
States / cities
Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 21, 2026, 3:27 PM EDT